|Day Low/High||4.23 / 4.38|
|52 Wk Low/High||2.15 / 6.41|
Thus far, there have been no surprises during this pharmaceutical company's discussions with the FDA about one of its products.
Here's our live coverage of the FDA review of Vivus's weight-loss drug, Qnexa.
Question and thoughts about the FDA's upcoming advisory panel to review Vivus' weight-loss drug.
Analysts are free to disclose NEJM studies about Arena weight-loss drug while media remains under embargo.
Intel price target higher at Citi and estimates are higher at Barclays and UBS.
Citigroup, MBIA, Apple, Brooks Automation among big market movers Tuesday
The FDA report says this name's weight-loss treatment is effective but the agency does have some questions about its safety.
The FDA posted a review of Vivus' Qnexa ahead of Thursday's advisory panel meeting.
FDA to evaluate obesity drug that would be the first new prescription treatment in a decade
It was a quiet week for the model portfolio holdings, but we watched our names closely as the market headed back up.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Shares of this biopharmaceutical company are trading higher this morning on recent good news for one of its products.
As the calendar turned the page into the third quarter this week, we added shares to three model portfolio names.
Arena's partnership with Eisai for its obesity drug is a win, but the terms are less than generous.
We added shares to a model portfolio holding on Friday, at the end of a week that painted a mixed economic picture.
Despite mixed economic news and quadruple-witching options expiration, it was a fairly quiet week for the model portfolio.
Biotech watchdog Adam Feuerstein answers readers' questions about drug and health care companies.
The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 11% this year.
During another week of roller coaster trading, we added shares to three model portfolio names and raised one rating.
During a volatile trading week marked by mixed economic data, we added shares to one model portfolio holding.
Market players are convinced the jobs number will be bullish, but it's hard to know how things will shake out, given data skewed by census jobs and hiring related to the oil spill.
Two of our health care names are trading higher today based on strong products and likely improving margins.
While riding the waves of market volatility, we added shares to two model portfolio holdings this week.
We added a new name to the model portfolio, expanded four holdings and raised one rating during this volatile week.
We are looking at five model portfolio names and offering a roadmap for what could be a volatile trading session.
This week, we added to our stake in a model portfolio energy holding and booked some profits from two other names.
This holding is trading 54% above our cost basis -- it's prudent to take some off the table here. Also, lowering our rating.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.